Establishment of patient-derived organoids and a characterization based drug discovery platform for treatment of gastric cancer.

ABSTRACT:

Background

Gastric cancer (GC) encompasses many different histological and molecular subtypes. It is a major driver of cancer mortality because of poor survival and limited treatment options. Personalised medicine in the form of patient-derived organoids (PDOs) represents a promising approach for improving therapeutic outcomes. The goal of this study was to overcome the limitations of current models by ameliorating organoid cultivation.

Methods

Organoids derived from cancer tissue were evaluated by haematoxylin and eosin staining, immunohistochemistry, mRNA, and whole-exome sequencing. Three representative chemotherapy drugs, 5-fluorouracil, docetaxel, and oxaliplatin, were compared for their efficacy against different subtypes of gastric organoids by ATP assay and apoptosis

SUBMITTER: Chen G 

PROVIDER: S-EPMC11323579 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature